Source : Monash IVF Group
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ImpediMed (IPD) has published a full peer-reviewed manuscript in Frontiers in Cardiovascular Medicine
  • Frontiers in Cardiovascular Medicine publishes peer-reviewed research articles across cardiovascular medicine to allow scientists and clinicians to advance their scientific knowledge and propose new theories
  • The publication demonstrates the clinical utility of ImpediMed’s SOZO device in monitoring heart failure patients
  • According to the findings, the extracellular fluid of total body water was significantly higher for those with heart failure, compared to the control population
  • ImpediMed is trading flat at 12 cents

Brisbane-based medical technology company ImpediMed (IPD) has published a full peer-reviewed manuscript in Frontiers in Cardiovascular Medicine.

Frontiers in Cardiovascular Medicine publishes peer-reviewed research articles across cardiovascular medicine to allow scientists and clinicians to advance their scientific knowledge and propose new theories.

The manuscript, titled “Clinical Utility of Fluid Volume Assessment in Heart Failure Patients Using Bioimpedance Spectroscopy”, demonstrates the clinical utility of ImpediMed’s SOZO device in monitoring heart failure patients.

It describes the bioimpedance spectroscopy (BIS) derived HF-Dex values and extracellular fluid expressed as a percentage of total body water in a clinical way that can be used by physicians to monitor fluid volume in heart failure patients.

SOZO is a non-invasive BIS device that delivers a precise snapshot of fluid status and tissue composition of a patient in less than 30 seconds.

The publication noted that the extracellular fluid of total body water was significantly higher for those with heart failure, compared to the control population, with no healthy subject’s total body water exceeding the 51 per cent threshold for fluid overload.

The manuscript also suggested that BIS measurements may provide a unique additional tool to aid in clinical decision making.

Additionally, the paper outlined four clinical settings in which SOZO can be used to track fluid volume changes in heart failure patients, like emergency departments, assessing at-risk heart failure patients and longitudinal management in nursing facilities.

“This study is a critical step in obtaining real world evidence for our HF-Dex application,” said Richard Carreon, Managing Director and CEO of ImpediMed.

“It demonstrates that SOZO can track patient fluid levels and that established normative range data can be useful in risk stratifying patients”.

ImpediMed is trading flat at 12 cents at 9:15 am AEST.

IPD by the numbers
More From The Market Herald

" Race Oncology (ASX:RAC) reports $1.8m in cash outflows

Race Oncology (ASX:RAC) reports $1.8 million in cash outflows
Imugene (ASX:IMU) - CEO, Leslie Chong

" Imugene (ASX:IMU) signs clinical trial agreement with Roche for lung cancer

Imugene (ASX:IMU) signs a clinical trial supply agreement with Roche to evaluate the combination of treatments…
Fiji Kava (ASZ:FIJ) - CEO and Managing Director, Dr Anthony Noble

" Fiji Kava (ASX:FIJ) hits quarterly revenue record

Fiji Kava (ASX:FIJ) has tabled a record quarterly revenue of $476,531 for the December quarter, up…